© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
April 18, 2021
Although curing advanced RCC is an admirable goal, there are many treatment options available on the horizon that result in substantial improvements in long-term outcomes.
March 30, 2021
Oncologists deciding what to do about coronavirus disease 2019 vaccines are not alone.
September 23, 2020
Immune checkpoint inhibitors blocking CTLA-4 or PD-1/PD-L1 often provide durable antitumor benefits to certain patients who respond to them; however, the percentage of responders is low, around 15% to 25%.
July 15, 2020
Agents developed to prevent myelosuppression are the latest chemoprotectants under investigation in the treatment of various solid tumor malignancies.